Announcement • Jul 08
Nasdaq to Delist the Common Stock of Athenex Nasdaq also announced on July 06, 2023 that it will delist the common stock of Athenex, Inc. The company’s securities were suspended on April 13, 2023, and have not traded on Nasdaq since that time. Announcement • May 26
Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index Athenex, Inc. has been dropped from NASDAQ Composite Index. Announcement • May 25
Athenex, Inc. announced delayed 10-Q filing On 05/23/2023, Athenex, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • May 24
Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case On May 16, 2023, Athenex, Inc. received written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, as a result of the Chapter 11 Case and in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1, the Nasdaq staff determined that the Company’s common stock will be delisted from Nasdaq. The Company does not intend to appeal this determination. Trading of the Company’s common stock will be suspended at the opening of business on May 25, 2023. Announcement • May 18
Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index Announcement • May 05
Athenex Receives Letter from the Listing Qualifications Staff of the Nasdaq as the Company No Longer Meets Nasdaq Listing Rule 5450(b)(3)(C) On April 27, 2023, Athenex, Inc. received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days and its number of publicly held shares, the Company no longer meets Nasdaq Listing Rule 5450(b)(3)(C), which requires listed companies to maintain a minimum market value of publicly held shares of at least $15 million. Nasdaq Listing Rule 5810(c)(3)(D) provides a compliance period of 180 calendar days, or until October 24, 2023, in which to regain compliance with this requirement. If the Company’s market value of publicly held shares is $15 million or more for a minimum of 10 consecutive business days during the 180-day compliance period, Nasdaq will provide written notice of compliance to the Company. If the Company fails to regain compliance with the Nasdaq continued listing standards, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. The notification has no immediate effect on the listing of the Company’s common stock on Nasdaq’s Global Select Market. The Company intends to monitor the closing bid price of its common stock and its number of publicly held shares and consider its available options in the event the market value of its publicly held shares remains below $15 million. Announcement • Feb 17
Athenex Announces Reverse Stock Split Athenex, Inc. announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023. Beginning tomorrow, February 15, 2023, the Company's common stock will trade on a split-adjusted basis. The Company's Board of Directors implemented the reverse stock split with the objective of regaining compliance with the $1.00 minimum bid price requirement of The Nasdaq Global Select Market. The Company has until March 14, 2023 to comply with this requirement. To evidence compliance with this requirement, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days by March 14, 2023. The Company's shares of common stock will continue to trade on The Nasdaq Global Select Market under the symbol "ATNX." The new CUSIP number for the Company's common stock post-reverse stock split is 04685N202. Announcement • Jan 04
Athenex Announces MHRA Decision on Oral Paclitaxel Athenex, Inc. announced that its proprietary Oral Paclitaxel formulation did not receive regulatory approval from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for metastatic breast cancer based solely on CMC issues. The MHRA application was not rejected based on any clinical efficacy or safety concerns expressed by the MHRA. MHRA regulations allow an applicant to request a re-examination of an opinion by an independent board which the Company plans to pursue. The Company views the identified CMC issues as addressable. Announcement • Dec 21
Athenex, Inc. Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer Athenex, Inc., reported that the Company’s oral paclitaxel plus encequidar in combination with a PD-1 inhibitor and carboplatin has graduated in the triple-negative subgroup of high-risk early-stage breast cancer. Oral paclitaxel, relative to intravenous paclitaxel, was associated with less neuropathy and was not associated with an increase in febrile neutropenia. Quantum Leap Healthcare Collaborative anticipates presenting these results at upcoming national meetings in Second Quarter of 2023. Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. Independent Director Bob Spiegel was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 04
Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.33 loss in 3Q 2021) Third quarter 2022 results: US$0.14 loss per share (improved from US$0.33 loss in 3Q 2021). Revenue: US$33.5m (up 3.8% from 3Q 2021). Net loss: US$19.4m (loss narrowed 46% from 3Q 2021). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Germany. Announcement • Oct 25
Athenex, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Athenex, Inc. announced that they will report Q3, 2022 results Pre-Market on Nov 03, 2022 Announcement • Sep 17
Athenex Receives Written Notification from Nasdaq Stating the Company Had Not Regained Compliance with the Rule and Was Ineligible to Obtain A Second 180 Calendar Day Period to Regain Compliance As previously reported, on March 18, 2022, Athenex, Inc. ("the Company") received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon the closing bid price of the Company's common stock for the last 30 consecutive business days, the Company no longer met Nasdaq Listing Rule 5550(a)(2) (the Rule"), which requires listed companies to maintain a minimum bid price of at least $1 per share. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until September 14, 2022, in which to regain compliance with the Rule. The Company did not regain compliance with the Rule by September 14, 2022, but requested a second 180 calendar period to regain compliance with the Rule. On September 15, 2022, the Company received written notification ("the Notification") from Nasdaq stating that the Company had not regained compliance with the Rule and was ineligible to obtain a second 180 calendar day period to regain compliance because it did not meet the Nasdaq Capital Market's minimum $5,000,000 Stockholders' Equity initial listing requirement as of June 30, 2022. Pursuant to the Notification, the Company's common stock is subject to delisting from Nasdaq pending the Company's opportunity to request a hearing before the Nasdaq Hearings Panel ("the Panel"). The Company intends to diligently pursue an appeal of the Notification before the Panel and regain compliance with the Rule. Under Nasdaq rules, the delisting of the Company's common stock will be stayed during the pendency of the appeal and during such time, the Company's common stock will continue to be listed on Nasdaq. While the Company did not meet the Nasdaq Capital Markets minimum $5,000,000 Stockholder's Equity initial listing requirement at June 30, 2022 it currently has stockholders' equity in excess of $5,000,000 and expects to have stockholders' equity in excess of $5,000,000 at September 30, 2022. While the Company plans to request an appeal before the Panel on or before September 22, 2022, if the Company does not request a hearing before the Panel by such date, the Company's common stock will be scheduled for delisting at the opening of business on September 26, 2022. Announcement • Aug 12
Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $29.995333 million. Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $29.995333 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 35,333,334
Price\Range: $0.75
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 4,666,666
Price\Range: $0.749 Announcement • Aug 05
Dr. Reddy's, Intas Reportedly in Talks to Buy Athenex Intas Pharmaceuticals Limited and Dr. Reddy's Laboratories Limited (BSE:500124) are in talks to acquire Athenex, Inc. (NasdaqGS:ATNX) in a $200 million - $250 million deal, as the US-based biotechnology firm looks to sell a controlling stake. The two Indian pharma companies are competing with a handful of mid-market healthcare-focused private equity funds in the US, people with knowledge of the matter told ET. Athenex, which is into the development of cell therapies to treat cancers, had hired investment advisory firm Cowen Inc. to run a formal process to find a buyer. "A formal process has started and the first round of offers have come in," said one of the people. "Intas and Dr Reddy's are the two Indian firms in the race at present. A transaction could be concluded during the current quarter." A mail sent to Athenex on Tuesday remained unanswered at the time of going to press Thursday. Intas and Dr Reddy's also did not respond to emails seeking comment. Reported Earnings • Jul 29
Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021) Second quarter 2022 results: US$0.21 loss per share (up from US$0.33 loss in 2Q 2021). Revenue: US$31.5m (up 44% from 2Q 2021). Net loss: US$23.8m (loss narrowed 31% from 2Q 2021). Over the next year, revenue is forecast to grow 4.6%, compared to a 31% growth forecast for the industry in Germany. Announcement • Jul 22
Athenex, Inc. to Report Q2, 2022 Results on Jul 28, 2022 Athenex, Inc. announced that they will report Q2, 2022 results at 9:30 AM, US Eastern Standard Time on Jul 28, 2022 Announcement • Jul 12
TiHe Capital (Beijing) Co. Ltd. agreed to acquire Chongqing Taihao Pharmaceutical Co., Ltd. and Athenex Pharmaceuticals (Chongqing) Limited from Athenex, Inc. (NasdaqGS:ATNX) for CNY 124 million. TiHe Capital (Beijing) Co. Ltd. agreed to acquire Chongqing Taihao Pharmaceutical Co., Ltd. and Athenex Pharmaceuticals (Chongqing) Limited from Athenex, Inc. (NasdaqGS:ATNX) for CNY 124 million on July 7, 2022. At the closing of this transaction, TiHe Capital will pay at least 70% of the Purchase Price to Athenex. The remainder of the Purchase Price will be paid in cash, with 20% of the Purchase Price to be paid within three months after the closing Date and the remaining balance of the Purchase Price to be paid within six months after the closing Date. The closing of this transaction is subject to closing conditions, including obtaining the approval of CQ and the consent of certain governmental authorities in China, and other customary closing conditions. Either party may terminate the Agreement if closing has not occurred by September 30, 2022, or a later date as agreed upon by TiHe Capital and Athenex. Announcement • Jun 09
Athenex, Inc. Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to Lead Its Clinical Development, Clinical Operations, and Regulatory Affairs Functions Athenex, Inc. announced the appointment of Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to lead its clinical development, clinical operations, and regulatory affairs functions. He will be replacing Kurt Gunter, MD, who has decided to pursue other opportunities outside of cell therapy. Dr. Cohen is a hematologist/oncologist with over 25 years of oncology clinical research and drug development experience in both solid tumors and hematological malignancies. He has held leadership positions of increasing responsibility at Pharmacia, Sanofi-Aventis, and Pfizer, including Vice President of Late-Phase Clinical Development at Pfizer Oncology where he was involved in multiple successful regulatory submissions of new molecularly targeted cancer drugs such as SUTENT® (sunitinib), XALKORI® (crizotinib), and IBRANCE® (palbociclib). More recently, Dr. Cohen was Head of Clinical Development at EUSA Pharma then Chief Medical Officer at Biosight Pharmaceuticals, having been a principal investigator on several clinical trials in the past and co-authored numerous peer-reviewed publications. Darrel received his MD and PhD degrees in Medicine and Microbiology from Boston University School of Medicine, trained as a resident in Internal Medicine at Georgetown University Medical Center, and completed a fellowship in Hematology/Oncology at Duke University Medical Center. Board Change • Jun 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. Independent Director Bob Spiegel was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • May 12
Athenex, Inc. Provides Sales Guidance for the Full Year 2022 Athenex, Inc. provides sales guidance for the full year 2022. For the period, the company expects product sales growth to be in the range of 20-25% over the prior year period, versus the prior range of 15-20% growth, year-over-year, due to the strong performance of company’s APD/APS division, earlier than expected NY State license, and the robust pipeline of launches planned for the remainder of 2022. Reported Earnings • May 11
First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.27 loss in 1Q 2021) First quarter 2022 results: US$0.27 loss per share (down from US$0.27 loss in 1Q 2021). Revenue: US$29.7m (down 28% from 1Q 2021). Net loss: US$30.0m (loss widened 20% from 1Q 2021). Over the next year, revenue is forecast to grow 10%, compared to a 37% growth forecast for the industry in Germany. Board Change • May 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. Independent Director Bob Spiegel was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • May 02
Athenex, Inc. to Report Q1, 2022 Results on May 10, 2022 Athenex, Inc. announced that they will report Q1, 2022 results Pre-Market on May 10, 2022 Announcement • Apr 26
Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular Meetings of ASTCT and CIBMTR Athenex, Inc. announced data from the ANCHOR Phase 1 study of KUR-502 during an oral presentation by Carlos Ramos, M.D., professor, Center for Cell and Gene Therapy, Baylor College of Medicine, at the Tandem Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT), and the Center for International Blood & Marrow Transplant Research (CIBMTR), taking place April 23 to 26, in Salt Lake City, UT. Highlights from the interim update include response data from seven evaluable patients, including two additional patients who were previously too early to assess (1 NHL, 1 ALL): One patient with NHL had stable disease (SD), and a second patient with ALL had progressive disease (PD) at the 4-week assessment - Two CRs persisted for more than 6 months with one at 34 weeks and still ongoing - Two responses (1 CR and 1 PR) were observed in patients who had relapsed after previous autologous CAR-T therapy - Excellent safety with no immune effector cell-associated neurotoxicity syndrome (ICANS) and no graft versus host disease (GvHD) attributable to CAR-NKT cells - Grade 1 cytokine release syndrome (CRS) in 2 ALL patients - Patient B1 from the ALL cohort had a complete response with incomplete hematologic recovery (CRi). About the Phase I Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Patients with Relapsed or Refractory B-Cell Malignancies (ANCHOR). The Phase 1 study is an open-label, dose-escalation trial. NKT cells were isolated from the leukapheresis product of one HLA-unmatched healthy individual, transduced with the CAR, expanded ex vivo for 14 days (99.8% NKT purity), and cryopreserved. Subjects were treated in an outpatient setting and received 107 (DL 1) or 3×107 (DL 2) CAR-NKT cells per square meter of body surface area following lymphodepleting conditioning with cyclophosphamide/fludarabine. Adverse events were evaluated per NCI criteria. When accessible, patients underwent core biopsies of an involved site at 2-5 weeks post-infusion. Response to therapy was assessed at 4 weeks per Lugano Criteria (for NHL) or NCCN guidelines (for ALL). Announcement • Apr 16
Kim Campbell Not to Stand for Re-Election to the Athenex Board of Directors At the 2022 Annual Meeting of Stockholders On April 13, 2022, Kim Campbell informed the Board of Directors of Athenex, Inc. (the Company") that she will not stand for re-election to the Board of Directors at the 2022 annual meeting of stockholders (the Annual Meeting") and will retire from the Board of Directors as of the conclusion of the Annual Meeting when her current term expires. After the Annual Meeting, the size of the Board will decrease from nine to eight directors. Ms. Campbell's retirement is not related to any disagreement with the Company on any matter relating to the Company's operations, policies or practices. In connection with her retirement, the Board of Directors approved the acceleration of the vesting of Ms. Campbell's unvested restricted stock units and stock options, which will vest at the conclusion of the Annual Meeting. Reported Earnings • Mar 19
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: US$1.85 loss per share (down from US$1.67 loss in FY 2020). Revenue: US$120.2m (down 17% from FY 2020). Net loss: US$192.0m (loss widened 35% from FY 2020). Products in clinical trials Phase I: 5 Phase II: 1 Revenue missed analyst estimates by 4.7%. Over the next year, revenue is expected to shrink by 4.4% compared to a 71% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings. Announcement • Feb 24
Athenex Announces Appoints Joe Annoni as Chief Financial Officer Athenex, Inc. announced that Mr. Joe Annoni will join Athenex as its new Chief Financial Officer and Officer of the Company, effective immediately. Mr. Annoni is an accomplished financial professional and has enjoyed a multi-faceted career in private equity, investment banking, and Big4 Advisory, with over 20 years of corporate finance experience. Prior to joining Athenex, Mr. Annoni served as Managing Director with GFW Partners, a boutique advisory firm. Prior to GFW, Joe was a founding member of NHA Capital where he led private equity and venture capital investment activities. Before co-founding NHA, he was a Vice President at investment banking firm Roth Capital where he led M&A and capital market advisory engagements. Early in his career, Joe was employed at PricewaterhouseCoopers advising Fortune 100 clients across a broad range of engagements including strategy, acquisitions, divestitures, restructuring, and operational improvements. Announcement • Feb 16
ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX). ImmunityBio, Inc. (NasdaqGS:IBRX) entered into a definitive agreement to acquire Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX) for approximately $38.17 million on January 7, 2022. The purchase prize is subject to adjustment subject to adjustment at Closing and not to exceed $40 million. Proceeds from the sale will be used to service the Athenex, Inc debt obligations and for other general corporate purposes. The transaction is subject to customary closing conditions, including obtaining consent of certain 3rd party organizations and a lender of Athenex and is expected to close in the first quarter of 2022. Received Receipt of the consents of the Empire State Development , the County of Chautauqua Industrial Development Agency, Fort Schuyler Management Corporation. Kenneth M. Silverman, Dakota J. Forsyth, Thomas D. Kearns, Dov B. Brandstatter and Kyle C. Bisceglie of Olshan Frome Wolosky LLP acted as a legal advisor to ImmunityBio, Inc. Alexander R. McClean of Harter, Secrest & Emery LLP acted as a legal advisor to Athenex, Inc.
ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX) on February 14, 2022. Announcement • Nov 30
Athenex, Inc. Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review Athenex, Inc. announced that its Marketing Authorization Application (MAA) for oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of advanced breast cancer has been validated by the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency (MHRA) for review . The application qualifies for a 150 day assessment by which a decision on approvability of the product will be provided. A single pivotal Phase III study of Oral Paclitaxel (KX-ORAX-001) served as the basis of the MAA. The study was a randomized, controlled clinical trial designed to compare the safety and efficacy of Oral Paclitaxel monotherapy versus IV paclitaxel monotherapy in patients with metastatic breast cancer. As previously reported, the study successfully achieved its primary endpoint showing statistically significant improvement in overall response rate (ORR), along with a lower incidence of neuropathy, for Oral Paclitaxel compared to IV paclitaxel. Announcement • Nov 24
Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer At SABCS 2021 Athenex announced that an abstract for a subgroup analysis of its Phase 3 study of oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of metastatic breast cancer has been accepted for poster presentation at the 2021 San Antonio Breast Cancer Symposium (SABCS), to be held from December 7 to December 10, 2021. The abstract and poster provide data from a post hoc, subgroup analysis of safety, progression free survival and overall survival of patients with elevated liver enzymes (AST or bilirubin) from study KX-ORAX-001, a Phase 3 study of weekly Oral Paclitaxel plus Encequidar vs IV Paclitaxel 175mg/m2 every three weeks. 402 subjects were randomized in a 2:1 ratio to Oral Paclitaxel and Encequidar vs IV Paclitaxel. Prior to treatment, 122 patients out of 402 total study patients (30.3%) had elevated AST or bilirubin, primarily mild hepatic dysfunction. For patients with elevated liver enzymes receiving Oral Paclitaxel, the median survival was 18.9 months compared to 10.1 months for patients receiving IV Paclitaxel: with a hazard ratio of 0.593 (95.5% CI 0.382 - 0.921) favoring Oral Paclitaxel. Although metastatic breast cancer patients with mild hepatic dysfunction at baseline are at increased risk of early serious neutropenic and infectious/septic complications this risk may be counterbalanced by a potential increase in efficacy after treatment with Oral Paclitaxel. Details of the poster presentation is as follows: Abstract Title: Oraxol + Encequidar (OPac+E) vs IV paclitaxel (IVPac) in the treatment of patients with metastatic breast cancer (mBC) (Study KX-ORAX-001): Subgroup survival analysis of patients with hepatic dysfunction; Session: 1; Program Number: P1-16-05; Date and Time: December 8, 2021. 7:00 am CT. Recent Insider Transactions • Nov 19
Independent Director recently bought €54k worth of stock On the 17th of November, Jinn Wu bought around 30k shares on-market at roughly €1.80 per share. In the last 3 months, they made an even bigger purchase worth €136k. Despite this recent purchase, insiders have collectively sold €1.7m more in shares than they bought in the last 12 months. Reported Earnings • Nov 05
Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020) The company reported a soft third quarter result with weaker revenues and control over costs, although losses reduced. Third quarter 2021 results: Revenue: US$32.3m (down 9.0% from 3Q 2020). Net loss: US$36.1m (loss narrowed 2.0% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Sep 15
Independent Director recently bought €136k worth of stock On the 14th of September, Jinn Wu bought around 50k shares on-market at roughly €2.72 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €1.7m more in shares than they bought in the last 12 months. Executive Departure • Aug 18
Chief Financial Officer Randoll Sze has left the company On the 13th of August, Randoll Sze's tenure as Chief Financial Officer ended after 3.0 years in the role. As of June 2021, Randoll still personally held only 6.00k shares (€23k worth at the time). Randoll is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 4.42 years. Reported Earnings • Aug 08
Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020) The company reported a soft second quarter result with weaker revenues and control over costs, although losses reduced. Second quarter 2021 results: Revenue: US$21.9m (down 45% from 2Q 2020). Net loss: US$34.3m (loss narrowed 15% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Announcement • Jun 05
Athenex, Inc. Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program Athenex, Inc. announced that the Company presented data from a phase I pharmacokinetic study of oral docetaxel plus encequidar (“oral docetaxel”) and updated data from the phase III study of oral paclitaxel plus encequidar (“oral paclitaxel”) illustrating tumor responses by molecular subtype. The data are being presented in two posters at the American Society for Clinical Oncology 2021 (ASCO2021) Virtual Scientific Program, being held from June 4th to June 8th, 2021. Data were presented from the open-label, two-way crossover phase I pharmacokinetic study of oral docetaxel vs IV docetaxel, which demonstrated the drug was well tolerated with no dose limiting toxicities, or drug-related serious adverse events. The mean absolute bioavailability was 15.9% (range 8% to 25%) with PK exposure becoming non-linear at 300 mg/m2. Based on these results and the results of other related studies, oral docetaxel 300 mg/m2 as divided doses is being further evaluated. Updated data were presented from the phase III trial of oral paclitaxel, specifically tumor response rates by receptor subtype. Athenex presented the results of a post-hoc subgroup efficacy analysis based on additional tumor subtype data. Overall response rate in the intent-to-treat (ITT) population demonstrated that oral paclitaxel was superior to IV paclitaxel with confirmed response rates of 35.8% versus 23.4%, respectively (p=0.0107). Announcement • May 23
Athenex, Inc. Announces Klisyri® (Tirbanibulin) Receives Positive Chmp Opinion from the European Medicines Agency (Ema) for the Treatment of Actinic Keratosis of the Face or Scalp Athenex, Inc. announced that its partner, Almirall, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the regulatory approval of Klisyri (tirbanibulin), indicated for the topical treatment of actinic keratosis (AK) of the face or scalp. Tirbanibulin is a novel, topical first-in-class microtubule inhibitor with a selective antiproliferative mechanism of action that represents a significant step forward in the treatment of AK due to its short treatment protocol (once daily application for 5 days), proven efficacy, and safety profile. Announcement • May 18
Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKTCells in Neuroblastoma at ASGCT Annual Meeting Athenex, Inc. announced that investigators from Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine presented new clinical data from the ongoing GINAKIT2 phase 1 study of Athenex’s cell therapy candidate KUR-501 targeting GD2 in neuroblastoma at the American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting. Observed responses to date in 11 evaluable, heavily pretreated patients with neuroblastoma, include one complete response (CR) and one partial response (PR). Four additional patients have exhibited stable disease (SD). The durations of response for the CR and PR were approximately 5 and 3 months, respectively. No patients experienced grade 2 or higher toxicities related to the GD2-CAR NKTs. Post-treatment tumor biopsies showed GD2-CAR NKTs homing to metastatic lesions at all dose levels. The CAR-NKT AUC normalized to disease burden (AUC/Curie score using MIBG scan quantified tumor burden) appears to be associated with response to therapy. KUR-501 [4] is an autologous product in which NKT cells are engineered with a CAR targeting GD2, which is expressed on almost all neuroblastoma tumors, as well as other malignancies. KUR-501 is being tested in the phase 1 GINAKIT2 clinical study (NCT03294954) in patients with R/R high risk neuroblastoma. The single-arm study will evaluate six dose levels of KUR-501 with patients receiving pre-dose lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine. Neuroblastoma is a pediatric cancer and patients with R/R high risk neuroblastoma have a poor prognosis and a significant unmet medical need. The KUR-501 development program is also designed to provide autologous proof-of-concept for CAR-NKT cells in solid tumors using a validated target. The GINAKIT2 study is supported by Athenex, Inc., which acquired Kuur Therapeutics in May 2021, and Alex’s Lemonade Stand Foundation, is conducted by Athenex’s collaborator, BCM, and is currently recruiting patients. Reported Earnings • May 10
First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.24 loss in 1Q 2020) The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: US$41.0m (down 13% from 1Q 2020). Net loss: US$25.1m (loss widened 29% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Announcement • May 07
Athenex, Inc. Reaffirms Sales Guidance for the Year 2021 Athenex, Inc. reaffirmed sales guidance for the year 2021. The Company is affirming the guidance it provided on March 1, 2021, as it currently expects its product sales in 2021, excluding any royalties from Klisyri®, to be in line with 2020 levels. Announcement • May 06
Athenex, Inc. (NasdaqGS:ATNX) acquired Kuur Therapeutics Limited. Athenex, Inc. (NasdaqGS:ATNX) acquired Kuur Therapeutics Limited on May 4, 2021. Under the terms of the agreement, Athenex will pay $70 million upfront to Kuur shareholders and certain of its former employees and directors, comprised primarily of equity in Athenex common stock. Additionally, Kuur Therapeutics is eligible to receive up to $115 million of milestone payments, which may be paid, at Athenex’s sole discretion, in either cash or additional Athenex common stock or a combination of both. The board of directors of Athenex unanimously approved the transaction. Michal Berkner of Cooley (UK) LLP acted as legal advisor and SVB Leerink LLC acted as financial advisor to Athenex. Evan Knobloch of Horwood Marcus & Berk Chartered acted as legal advisor to Kuur Therapeutics.
Athenex, Inc. (NasdaqGS:ATNX) completed the acquisition of Kuur Therapeutics Limited on May 4, 2021. Announcement • Apr 24
Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Athenex, Inc Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Athenex, Inc. between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that- the data included in the Oral Paclitaxel and Encequidar New Drug Application (“NDA”) presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; the uncertainty over the results of the primary endpoint of objective response rate (“ORR”) at week 19 conducted by blinded independent central review (“BICR”); the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; the company’s Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; as a result, it was foreseeable that the FDA would not approve the Company’s NDA in its current form; and as a result, the company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. Announcement • Mar 25
Robbins LLP Reminds Shareholders that Athenex, Inc. is Being Sued for Misleading Shareholders Robbins LLP reminds shareholders that a purchaser of Athenex, Inc. filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between August 7, 2019 and February 26, 2021. According to the complaint, on August 7, 2019, Athenex announced topline data showing that oral paclitaxel and encequidar met the primary efficacy endpoint with statistically significant improvement over IV paclitaxel in a Phase 3 pivotal study in metastatic breast cancer (the ‘Study’). The Company stated that it was preparing its New Drug Application (‘NDA’) for submission to the Federal Drug Administration (‘FDA’) and touted their Study over the next several months. On September 1, 2020, Athenex announced that the FDA had accepted for filing its NDA for Oral Paclitaxel and Encequidar in metastatic breast cancer with priority review with a target action date of February 28, 2021, and that ‘the FDA has communicated that it is not currently planning to hold an advisory committee meeting to discuss the application.’ On December 9, 2020, Athenex announced it had presented updated Study data at the 2020 San Antonio Breast Cancer Symposium that ‘support the clinical rationale for oral paclitaxel as an efficacious and tolerable treatment option for people living with metastatic breast cancer.’ Despite these positive statements, on March 1, 2021, Athenex announced that the FDA issued a CRL, which indicates that the review cycle for an application is complete and that the application is not ready for approval in its present form. According to the Company, ‘the FDA indicated its concern of safety risk to patients in terms of an increase in neutropenia-related sequalae on the Oral Paclitaxel arm compared with IV paclitaxel arm,’ among others. The FDA recommended that Athenex conduct a new adequate and well-conducted clinical trial. Recent Insider Transactions • Mar 11
Insider recently sold €1.6m worth of stock On the 4th of March, Wei Zuo sold around 420k shares on-market at roughly €3.75 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €388k more than they bought in the last 12 months. Recent Insider Transactions • Mar 06
Independent Director recently sold €385k worth of stock On the 3rd of March, Jinn Wu sold around 98k shares on-market at roughly €3.93 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought €1.7m more than they sold in the last 12 months. Announcement • Mar 05
The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm The Schall Law Firm announced the filing of a class action lawsuit against Athenex, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 7, 2019 and February 26, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before May 3, 2021. According to the Complaint, the Company made false and misleading statements to the market. The company announced on March 1, 2021, that the FDA had issued a complete response letter (“CRL”) for the company's New Drug Application (“NDA”) for oral paclitaxel plus encequidar for the treatment of metastatic breast cancer. The FDA’s CRL cited patient safety risks and uncertainty related to primary endpoint results for the objective response rate (“ORR”) which may have introduced bias in the blinded clinical review. The FDA recommended the Company “conduct a new adequate and well-conducted clinical trial in a patient population with metastatic breast cancer representative of the population in the U.S." The FDA also indicated that the toxicity would require a risk mitigation strategy for the treatment to be approved. Based on this news, shares of Athenex fell by 55% in one day. Announcement • Mar 03
Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer Athenex, Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the company’s New Drug Application (NDA) for oral paclitaxel plus encequidar for the treatment of metastatic breast cancer. The FDA issues a CRL to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form. In the CRL, the FDA indicated its concern of safety risk to patients in terms of an increase in neutropenia-related sequelae on the Oral Paclitaxel arm compared with the IV paclitaxel arm. The FDA also expressed concerns regarding the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by blinded independent central review (BICR). The Agency stated that the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR. The agency recommended that Athenex conduct a new adequate and well-conducted clinical trial in a patient population with metastatic breast cancer representative of the population in the U.S. The Agency determined that additional risk mitigation strategies to improve toxicity, which may involve dose optimization and /or exclusion of patients deemed to be at higher risk of toxicity, are required to support potential approval of the NDA. Athenex plans to request a meeting with the FDA to discuss the Agency’s response, engage in a dialogue on the design and scope of a clinical trial to address the FDA’s requirements and align on the next steps required to obtain approval. Reported Earnings • Mar 02
Full year 2020 earnings released: US$1.72 loss per share (vs US$1.67 loss in FY 2019) The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: US$144.4m (up 43% from FY 2019). Net loss: US$146.2m (loss widened 18% from FY 2019). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Mar 02
New 90-day low: €4.52 The company is down 59% from its price of €11.00 on 02 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €142 per share. Analyst Estimate Surprise Post Earnings • Mar 02
Revenue beats expectations Revenue exceeded analyst estimates by 5.8%. Over the next year, revenue is expected to shrink by 4.0% compared to a 55% growth forecast for the Biotechs industry in Germany. Announcement • Feb 23
Athenex, Inc. to Report Q4, 2020 Results on Mar 01, 2021 Athenex, Inc. announced that they will report Q4, 2020 results Pre-Market on Mar 01, 2021 Announcement • Feb 12
Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy and Safety of Klisyri® (tirbanibulin) Athenex, Inc. announced that the New England Journal of Medicine (NEJM) has published the results from the pivotal Phase III trials of Klisyri® ointment for actinic keratosis of the face or scalp in the February 11, 2021. The Phase III trials evaluated the efficacy and safety of Klisyri® ointment 1% (10 mg/g) in adults with actinic keratosis on the face or scalp and included 702 patients across 62 sites in the United States. Enrollment of patients was controlled to achieve a 2:1 ratio of facial: scalp treatment areas. Patients were randomly assigned in a 1:1 ratio to receive Klisyri® ointment or vehicle ointment, which was self-administered to a contiguous treatment area of 25cm2 on the face or scalp containing 4-8 typical AK lesions once daily for five consecutive days. Both Phase III trials, KX01-AK-003 and KX01-AK-004, met the primary endpoint, which was defined as 100% clearance of AK lesions at Day 57 within the face or scalp treatment areas, each trial achieving a highly statistically significant result (p<0.0001). In KX01-AK-003, complete clearance was observed in 44% of the patients treated with Klisyri® versus 5% for those treated with vehicle, and in KX01-AK-004, complete clearance was observed in 54% of the patients treated with Klisyri® versus 13% for vehicle. Furthermore, tirbanibulin also achieved the secondary endpoint of partial (=75%) clearance of lesions in each trial (68% of patients receiving Klisyri® versus 16% receiving vehicle in KX01-AK-003, and 76% versus 20% respectively in KX01-AK-004). Both results were again highly statistically significant (p<0.0001). In both trials, patient-reported adverse events were mostly transient mild application-site pruritus and application-site pain. No patients experienced a serious adverse event or discontinuation due to Klisyri® or vehicle in either clinical trial. Signs of local skin reactions assessed by investigators were mostly mild to moderate erythema, flaking or scaling that peaked at day 8 (maximum mean composite local skin reaction score =4.3 out of 18 across both trials) and resolved spontaneously in about 2 weeks. Is New 90 Day High Low • Feb 11
New 90-day high: €11.80 The company is up 16% from its price of €10.20 on 12 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €89.55 per share. Announcement • Dec 18
Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp Athenex, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Klisyri® (tirbanibulin) for the topical treatment of actinic keratosis (AK) on the face or scalp. Klisyri is the first FDA approved branded proprietary product for Athenex and will be launched in partnership with Almirall in the U.S. during the first quarter of 2021. Klisyri will be manufactured by Athenex, highlighting the vertically integrated capabilities of the company ranging from a preclinical lead to a developed product for market launch. The FDA approved Klisyri based on the data from two pivotal, randomized, double-blind, vehicle-controlled Phase III studies (KX01-AK-003 and KX01-AK-004) that evaluated the efficacy and safety of Klisyri (tirbanibulin) ointment 1% in 702 adults with actinic keratosis of the face or scalp. Tirbanibulin demonstrated complete clearance of actinic keratosis lesions at day 57 in treated face or scalp areas in a significantly higher number of patients compared to vehicle. The most common adverse events were application site pruritus and pain reported by 9% and 10% of treated patients, respectively. Actinic keratosis is a pre-cancerous skin lesion and is the second most common diagnosis made by dermatologists in the United States. If left untreated, 10-15% of AK lesions will develop into skin cancers. Athenex has partnered with Almirall (Almirall, S.A., BME: ALM) to market Klisyri for the treatment of actinic keratosis on the face or scalp in the US and EU (including Russia) markets. In addition to the partnership with Almirall, Athenex has partnered with PharmaEssentia (6446.TWO) for actinic keratosis in Taiwan and has partnered with Xiangxue Pharmaceuticals (SHE:300147) for actinic keratosis in China, Hong Kong, and Macau. Is New 90 Day High Low • Dec 17
New 90-day low: €9.45 The company is down 12% from its price of €10.80 on 18 September 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €179 per share. Announcement • Dec 12
Athenex, Inc. Presents Updated Phase 3 Data on Survival and Tolerability Associated with Oral Paclitaxel and Encequidar in Patients with Metastatic Breast Cancer Athenex, Inc. announced the presentation of updated Phase 3 PFS and OS data demonstrating clinical benefits in efficacy and tolerability of oral paclitaxel versus IVP in patients with metastatic breast cancer (MBC). The findings further support the superiority of increased ORR observed with oral paclitaxel. These data were presented on December 9, 2020 during a spotlight poster presentation at the 2020 San Antonio Breast Cancer Symposium (SABCS). The spotlight poster presentation at SABCS featured an update on PFS and OS data from the Phase 3 trial. In the prespecified modified intent-to-treat (mITT) population (n = 360), the median PFS data showed a benefit for oral paclitaxel versus IVP (8.4 vs. 7.4 months, respectively; hazard ratio [HR] = 0.739; 95% confidence interval [CI]: 0.561, 0.974; p = 0.023). Median OS data also showed a benefit for oral paclitaxel versus IVP (23.3 months vs. 16.3 months, respectively; HR = 0.735; 95% CI: 0.556, 0.972; p = 0.026). In the intent-to-treat (ITT) population, which included all 402 randomized patients, the median PFS showed a benefit for oral paclitaxel versus IVP (8.4 months vs. 7.4 months, respectively; HR = 0.768; 95% CI: 0.584, 1.01; p = 0.046). The median OS data demonstrated a trend favoring oral paclitaxel versus IVP (22.7 months vs. 16.5 months, respectively; HR = 0.794; 95% CI: 0.607, 1.037; p = 0.082). Updated safety analyses of up to 112 weeks continue to demonstrate the reduction in incidence and severity of neuropathy favoring oral paclitaxel versus IVP: all grades of neuropathy were 22% vs. 64%, and grade 3 neuropathy was 2% vs. 15%. Also presented were data on the effect of prophylactic treatments on the incidence and severity of gastrointestinal-related adverse events. After approximately 30% of patients were enrolled, the Phase 3 trial protocol was amended to allow patients randomized to the oral paclitaxel arm to receive prophylactic pre-medications for gastrointestinal side effects. Overall gastrointestinal (GI)-related adverse events (AEs) were less frequent in the IV paclitaxel arm. GI-related AEs improved in the oral paclitaxel arm following the amendment, as measured by lower incidences of grade 2 vomiting before and after amendment (24% vs. 7%) and grade 2 diarrhea before and after amendment (27% vs. 16%). Oral paclitaxel has been granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic breast cancer with a PDUFA date of February 28, 2021. The Phase 3 trial randomized 402 patients with any metastatic breast cancer subtypes in a 2:1 ratio to receive either the oral paclitaxel regimen (205 mg/m2 of oral paclitaxel plus 15 mg of encequidar) for three days a week or the approved IV paclitaxel regimen (175 mg/m2) as a three-hour infusion every three weeks. The primary efficacy endpoint was overall response rate (ORR) confirmed at two consecutive timepoints by a blinded, independent radiology review that used RECIST v1.1 criteria to evaluate patients’ tumors for response. The trial was designed to demonstrate superiority of oral paclitaxel over IVP on the primary end point of ORR. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). The trial was not powered to demonstrate superiority of oral paclitaxel versus IVP on the secondary survival endpoints of PFS and OS. These secondary endpoints were not controlled for multiplicity. P-values presented are nominal. Athenex’s oral paclitaxel and encequidar (“oral paclitaxel”) is the first oral formulation of paclitaxel in late-stage development for the treatment of metastatic breast cancer (MBC), and is also in earlier stages of development for other malignancies. Encequidar, the cornerstone of Athenex’s Orascovery technology platform, is a highly specific and potent inhibitor of the transport protein called P-glycoprotein (P-gp) in the gastrointestinal (GI) tract. By localizing P-gp inhibitory activity in the GI tract, encequidar improves the absorption of chemotherapeutic agents while limiting the potential for unnecessary P-gp inhibition at other sites in the body. The potency, selectivity, and low absorption of encequidar enables the oral administration of IV chemotherapies, several of which are under development by Athenex. Analyst Estimate Surprise Post Earnings • Nov 07
Revenue beats expectations Revenue exceeded analyst estimates by 54%. Over the next year, revenue is forecast to grow 7.4%, compared to a 312% growth forecast for the Biotechs industry in Germany. Reported Earnings • Nov 07
Third quarter 2020 earnings released: US$0.44 loss per share The company reported a solid third quarter result with improved revenues and control over expenses, though losses increased. Third quarter 2020 results: Revenue: US$35.5m (up 83% from 3Q 2019). Net loss: US$36.8m (loss widened 5.9% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • Sep 24
Athenex, Inc. Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy Athenex, Inc. announced that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy targeting solid tumors that are NY-ESO-1 positive in HLA-A*02:01 positive patients. TCRT-ESO-A2 is being developed by Axis Therapeutics Limited, a joint venture between Athenex and Xiangxue Life Sciences Limited, a subsidiary of Xiangxue Pharmaceutical Co. Ltd. (Shenzhen Exchange: 300147). TCRT-ESO-A2 is similar to TAEST16001, an autologous cell-based therapy being developed simultaneously by XLifeSc for clinical application in China in that both therapies express the same affinity-enhanced TCR. Announcement • Sep 11
Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $110 million. Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 10,000,000
Price\Range: $11
Discount Per Security: $0.66 Announcement • Jul 31
Athenex, Inc. to Report Q2, 2020 Results on Aug 06, 2020 Athenex, Inc. announced that they will report Q2, 2020 results at 9:00 AM, Eastern Standard Time on Aug 06, 2020